Tag: MATCH Phase II
-
Resolution Therapeutics Announces Regenerative Macrophage Therapy Data for Cirrhosis at AASLD 2025
Overview: New Data Spotlight Regenerative Macrophage Therapy Resolution Therapeutics has announced key updates from its ongoing research into Regenerative Macrophage Therapy (RMT) for cirrhosis, with fresh data presented at AASLD 2025. The company highlighted early signals from the MATCH Phase II study showing that patients receiving non-engineered macrophages exhibit early improvements in liver function. In…
-
Resolution Therapeutics unveils regenerative macrophage therapy data for cirrhosis at AASLD 2025
Resolution Therapeutics presents hopeful data on regenerative macrophage therapy for cirrhosis at AASLD 2025 Resolution Therapeutics has announced new data from its portfolio of macrophage-based therapies at the AASLD 2025 conference. The company highlighted early clinical signals from the MATCH Phase II study, which evaluate the potential of non-engineered macrophages to repair cirrhotic livers and…
-
Resolution Therapeutics Unveils Early MATCH Phase II Data; Regenerative Macrophage Therapy Shows Promise for Cirrhosis at AASLD 2025
Groundbreaking DATA at AASLD 2025 Resolution Therapeutics presented new clinical and preclinical data at AASLD 2025 highlighting the potential of Regenerative Macrophage Therapy for cirrhosis. The company reported early improvements in liver function in the MATCH Phase II study using non-engineered macrophages, with associations to favorable long-term clinical outcomes. These findings position Resolution’s macrophage-based approach…